Genetic diagnosis of parkinsonian phenotype of Machado Joseph Diseasep (SCA-3) presenting with dopa induced dyskinesia
Objective: We report a rare type IV parkinsonian phenotype of MJD having a rare genetic mutation. SCA type 3 (SCA3), also known as Machado-Joseph disease…Demographic, clinical and genetic factors affecting amantadine response among patients with Parkinson disease
Objective: To identify factors that correlate with efficacy and tolerability of amantadine to predict therapeutic outcomes Background: Amantadine is the only commercially available medication to…The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson’s disease
Objective: We aimed to evaluate the association of selected polymorphisms of COMT, DRD2, ANKK1, and DAT genes and the occurrence of levodopa-induced motor complications in…Levodopa-induced dyskinesia and Huntington’s chorea: link to current motor control theories
Objective: Determine if there is a motor control hypothesis that could explain movement kinematics of Huntington’s disease (HD) chorea and Parkinson’s disease (PD) levodopa-induced dyskinesia…Results from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease
Objective: The objective of the Phase 2b-trial was to investigate efficacy and safety of three doses of Mesdopetam as adjunct treatment in patients with PD…Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis
Objective: Compare real-world clinical outcomes of Parkinson’s disease (PD) patients with moderate/severe motor fluctuations and/or dyskinesia treated with oral medications compared to device-aided therapies. Background:…Validation of the PD Home Diary for Assessment of Motor Fluctuations in Advanced Parkinson’s Disease
Objective: To determine the validity of the Parkinson’s disease (PD) home diary for quantification of motor states in patients with advanced PD and motor fluctuations.…Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias
Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…Movement disorders in pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis
Objective: Our aim was to investigate clinical characteristics and evolution of movement disorders (MD) in pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Background: Movement disorders account for…Determination of glycine transporter 1 levels with [3H]-NFPS binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia
Objective: To determine the distribution of the glycine transporter 1 (GlyT1) in brain areas implicated in parkinsonism and L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia in the 6-hydroxydopamine…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 40
- Next Page »